SEELOS THERAPEUTICS INC - SEEL STOCK NEWS

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced new data on SLS-004, its CRISPR-dCas9 gene therapy aimed at treating Parkinson's disease. The therapy demonstrated effective downregulation of alpha-synuclein and recovery of dopaminergic neurons in preclinical models. Seelos will present a poster titled SLS-004 - CRISPR-based epigenetic alpha-synuclein downregulation recovers loss of midbrain dopamine neurons in a humanized A53T Parkinson's rodent model at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit in San Francisco from February 21-23, 2023. This novel approach has shown promise in ameliorating Parkinson's disease-related cellular phenotypes, highlighting its potential as a future therapeutic option.

Seelos Therapeutics has initiated a Phase I ethnobridging study for SLS-002, an intranasal racemic ketamine therapy, focusing on safety and pharmacokinetics in Japanese and non-Asian subjects. This study, endorsed by the PMDA in Japan and FDA, aims to gather insights for future global trials targeting major depressive disorder (MDD) and suicidality. The 2019 data revealed over 1,000,000 emergency visits for suicide attempts in the U.S., underscoring the unmet need for effective treatments. SLS-002 demonstrates potential as a rapid intervention for severe depression and suicidality, aligning with the urgent market demand.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in the 12th Annual LifeSci Partners Corporate Access Event, taking place from January 9-11, 2023, in San Francisco, California. The company's chairman and CEO, Raj Mehra, emphasized the importance of discussing registrational studies for treatments related to acute suicidal ideation in major depressive disorder, amyotrophic lateral sclerosis, and spinocerebellar ataxia. In-person meetings will allow for direct engagement with senior management from over 200 life sciences companies.

Seelos Therapeutics (Nasdaq: SEEL) announced promising in vivo data demonstrating that a single dose of SLS-004 significantly increases the recovery of tyrosine hydroxylase-positive (TH+) dopaminergic neurons in a Parkinson's disease model. This reduction in α-synuclein production correlates with decreased PD symptoms such as tremor and rigidity. Seelos plans to discuss further developments during a conference call on December 15, 2022. The findings support SLS-004 as a potential disease-modifying gene therapy for Parkinson's, targeting the SNCA gene linked to α-synuclein protein levels.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced a research and development update conference call and webcast scheduled for December 15, 2022, from 1 PM to 3 PM ET. The event will showcase updates on therapies for central nervous system disorders, including SLS-002 for Acute Suicidal Ideation and Behavior, SLS-005 for amyotrophic lateral sclerosis, and gene therapy approaches SLS-004 and SLS-007 for Parkinson's disease. Key speakers include Dr. Evan P. Cohen and Raj Mehra, highlighting recent clinical developments and market opportunities for their therapies.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) will hold a research and development update conference call on December 15, 2022, from 1pm to 3pm ET. The call aims to update investors on ongoing registrational studies, market research, and preclinical data. Seelos is focused on therapies for central nervous system disorders and rare diseases, with key indications such as Major Depressive Disorder and ALS. The company anticipates a significant year ahead in 2023, filled with catalysts and advancements.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) will participate in the Guggenheim 4th Annual Immunology and Neurology Day on November 14-15, 2022. Raj Mehra, Ph.D., Chairman and CEO, is scheduled for 1x1 investor meetings and a presentation on November 15 at 1:35 PM ET. The company specializes in developing therapies for central nervous system disorders and rare diseases, with a portfolio targeting conditions such as Major Depressive Disorder, ALS, and Parkinson's disease. For more details, visit seelostherapeutics.com.

Seelos Therapeutics (Nasdaq: SEEL) announced its participation in the upcoming Wonderland event in Miami from November 3-5. The company will sponsor a Press Breakfast on November 4 to discuss the clinical study of its drug, SLS-002 (intranasal racemic ketamine), currently assessing its efficacy for treating suicidality in major depression. Seelos aims to address the unmet need for rapid treatments for suicidal patients, as over 1 million suicide attempts were recorded in U.S. emergency rooms in 2019.

Seelos Therapeutics (Nasdaq: SEEL) has initiated dosing the first patient in a registrational phase II/III study of SLS-005 (trehalose injection) targeting spinocerebellar ataxia type 3 (SCA3). This trial aims to enroll up to 245 participants globally, assessing the treatment's efficacy over a 52-week period. Seelos will present findings at the International Congress for Ataxia Research in Dallas, Texas, in November. SLS-005 has received Orphan Drug Designation from the FDA and EMA, representing a potential breakthrough for a condition lacking approved treatments.